These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 36701844)
1. Predictors of Post-chemoradiotherapy Pulmonary Complication in Locally Advanced Non-Small Cell Lung Cancer. Lee TH; Kang BH; Kim HJ; Wu HG; Lee JH Cancer Res Treat; 2023 Jul; 55(3):865-874. PubMed ID: 36701844 [TBL] [Abstract][Full Text] [Related]
2. Acute severe radiation pneumonitis among non-small cell lung cancer (NSCLC) patients with moderate pulmonary dysfunction receiving definitive concurrent chemoradiotherapy: Impact of pre-treatment pulmonary function parameters. Zhou Y; Yan T; Zhou X; Cao P; Luo C; Zhou L; Xu Y; Liu Y; Xue J; Wang J; Wang Y; Lu Y; Liang B; Gong Y Strahlenther Onkol; 2020 Jun; 196(6):505-514. PubMed ID: 31828393 [TBL] [Abstract][Full Text] [Related]
3. Impact of diffusing lung capacity before and after neoadjuvant concurrent chemoradiation on postoperative pulmonary complications among patients with stage IIIA/N2 non-small-cell lung cancer. Shin S; Choi YS; Jung JJ; Im Y; Shin SH; Kang D; Cho JH; Kim HK; Kim J; Zo JI; Shim YM; Park K; Ahn MJ; Ahn YC; Lee G; Cho J; Lee HY; Park HY Respir Res; 2020 Jan; 21(1):13. PubMed ID: 31924201 [TBL] [Abstract][Full Text] [Related]
4. Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer. Mayahara H; Uehara K; Harada A; Kitatani K; Yabuuchi T; Miyazaki S; Ishihara T; Kawaguchi H; Kubota H; Okada H; Ninomaru T; Shindo C; Hata A Radiat Oncol; 2022 Jan; 17(1):7. PubMed ID: 35033139 [TBL] [Abstract][Full Text] [Related]
5. Endostar acts as a pneumonitis protectant in patients with locally advanced non-small cell lung cancer receiving concurrent chemoradiotherapy. Chen K; Li S; Chen M; Jin Z; Sun X; Zhou S; Yang H BMC Cancer; 2024 Feb; 24(1):257. PubMed ID: 38395838 [TBL] [Abstract][Full Text] [Related]
6. Dose-volume parameters predict radiation pneumonitis after induction chemoradiotherapy followed by surgery for non-small cell lung cancer: a retrospective analysis. Katsui K; Ogata T; Watanabe K; Katayama N; Soh J; Kuroda M; Kiura K; Maeda Y; Toyooka S; Kanazawa S BMC Cancer; 2019 Nov; 19(1):1144. PubMed ID: 31771538 [TBL] [Abstract][Full Text] [Related]
7. [Expression and prognostic value of programmed cell death ligand 1 in patients with locally advanced and non-EGFR-mutated non-small cell lung cancer receiving concurrent chemoradiotherapy]. Xue WJ; Bi N; Yang L; Wang X; Dong JY; Zhang T; Wu LF; Wang LH Zhonghua Yi Xue Za Zhi; 2022 Feb; 102(6):406-411. PubMed ID: 35144339 [No Abstract] [Full Text] [Related]
8. Radiation pneumonitis after definitive concurrent chemoradiotherapy with cisplatin/docetaxel for non-small cell lung cancer: Analysis of dose-volume parameters. Katsui K; Ogata T; Watanabe K; Katayama N; Kuroda M; Kiura K; Hiraki T; Maeda Y; Toyooka S; Kanazawa S Cancer Med; 2020 Jul; 9(13):4540-4549. PubMed ID: 32364685 [TBL] [Abstract][Full Text] [Related]
9. Comparison of the Efficacy and Toxicity of Concurrent Chemoradiotherapy and Durvalumab and Concurrent Chemoradiotherapy Alone for Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node Metastasis. Abe T; Iino M; Saito S; Aoshika T; Ryuno Y; Ohta T; Igari M; Hirai R; Kumazaki YU; Miura YU; Kaira K; Kagamu H; Noda SE; Kato S Anticancer Res; 2023 Feb; 43(2):675-682. PubMed ID: 36697072 [TBL] [Abstract][Full Text] [Related]
10. Abnormal pulmonary function tests predict the development of radiation-induced pneumonitis in advanced non-small cell lung Cancer. Torre-Bouscoulet L; Muñoz-Montaño WR; Martínez-Briseño D; Lozano-Ruiz FJ; Fernández-Plata R; Beck-Magaña JA; García-Sancho C; Guzmán-Barragán A; Vergara E; Blake-Cerda M; Gochicoa-Rangel L; Maldonado F; Arroyo-Hernández M; Arrieta O Respir Res; 2018 Apr; 19(1):72. PubMed ID: 29690880 [TBL] [Abstract][Full Text] [Related]
11. Real-world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non-small cell lung cancer. Huang Y; Zhao JJ; Soon YY; Wong A; Aminkeng F; Ang Y; Asokumaran Y; Low JL; Lee M; Choo JRE; Chan G; Kee A; Tay SH; Goh BC; Soo RA Thorac Cancer; 2022 Nov; 13(22):3152-3161. PubMed ID: 36177913 [TBL] [Abstract][Full Text] [Related]
12. [Outcome of concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer patients]. Liu L; Wang X; Ji Z; Wang J; Bi N; Hui Z; Lyu J; Liang J; Zhou Z; Feng Q; Chen D; Zhang H; Xiao Z; Yin W; Wang L Zhonghua Zhong Liu Za Zhi; 2015 Nov; 37(11):863-7. PubMed ID: 26887520 [TBL] [Abstract][Full Text] [Related]
13. Impact of interstitial lung abnormality on survival after adjuvant durvalumab with chemoradiotherapy for locally advanced non-small cell lung cancer. Kashihara T; Nakayama Y; Okuma K; Takahashi A; Kaneda T; Katagiri M; Nakayama H; Kubo Y; Ito K; Nakamura S; Takahashi K; Inaba K; Murakami N; Saito T; Okamoto H; Itami J; Kusumoto M; Ohe Y; Igaki H Radiother Oncol; 2023 Mar; 180():109454. PubMed ID: 36640944 [TBL] [Abstract][Full Text] [Related]
14. Radical radiotherapy or chemoradiotherapy for inoperable, locally advanced, non-small cell lung cancer: Analysis of patient profile, treatment approaches, and outcomes for 213 patients at a tertiary cancer center. Shrimali RK; Nallathambi C; Saha A; Das A; Prasath S; Mahata A; Arun B; Mallick I; Achari R; Dabkara D; Thambudorai R; Chatterjee S Indian J Cancer; 2018; 55(2):125-133. PubMed ID: 30604722 [TBL] [Abstract][Full Text] [Related]
15. PET-detected pneumonitis following curative-intent chemoradiation in non-small cell lung cancer (NSCLC): recognizing patterns and assessing the impact on the predictive ability of FDG-PET/CT response assessment. Iravani A; Turgeon GA; Akhurst T; Callahan JW; Bressel M; Everitt SJ; Siva S; Hofman MS; Hicks RJ; Ball DL; Mac Manus MP Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1869-1877. PubMed ID: 31190177 [TBL] [Abstract][Full Text] [Related]
16. Radiation pneumonitis in patients with non-small-cell lung cancer receiving chemoradiotherapy and an immune checkpoint inhibitor: a retrospective study. Jang JY; Kim SS; Song SY; Kim YJ; Kim SW; Choi EK Radiat Oncol; 2021 Dec; 16(1):231. PubMed ID: 34863244 [TBL] [Abstract][Full Text] [Related]
17. Effect of durvalumab on local control after concurrent chemoradiotherapy for locally advanced non-small cell lung cancer in comparison with chemoradiotherapy alone. Abe T; Saito S; Iino M; Aoshika T; Ryuno Y; Ohta T; Igari M; Hirai R; Kumazaki Y; Miura Y; Kaira K; Kagamu H; Noda SE; Kato S Thorac Cancer; 2021 Jan; 12(2):245-250. PubMed ID: 33289347 [TBL] [Abstract][Full Text] [Related]
19. Factors Associated With Early Mortality in Patients Treated With Concurrent Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer. Warner A; Dahele M; Hu B; Palma DA; Senan S; Oberije C; Tsujino K; Moreno-Jimenez M; Kim TH; Marks LB; Rengan R; De Petris L; Ramella S; De Ruyck K; De Dios NR; Bradley JD; Rodrigues G Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):612-20. PubMed ID: 26867890 [TBL] [Abstract][Full Text] [Related]
20. Tumor cavitation in patients with stage III non-small-cell lung cancer undergoing concurrent chemoradiotherapy: incidence and outcomes. Phernambucq EC; Hartemink KJ; Smit EF; Paul MA; Postmus PE; Comans EF; Senan S J Thorac Oncol; 2012 Aug; 7(8):1271-5. PubMed ID: 22659960 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]